Brief: Celldex Reports Results From Phase 2 Study Of Barzolvolimab In Prurigo Nodularis
BRIEF-Celldex Reports Results From Phase 2 Study Of Barzolvolimab In Prurigo Nodularis July 21 (Reuters) - Celldex Therapeutics Inc CLDX.O:
CELLDEX REPORTS RESULTS FROM PHASE 2 STUDY OF BARZOLVOLIMAB IN PRURIGO NODULARIS
CELLDEX THERAPEUTICS - PHASE 2 STUDY OF BARZOLVOLIMAB IN PRURIGO NODULARIS DID NOT MEET KEY EFFICACY OBJECTIVES
CELLDEX THERAPEUTICS - PHASE 3 CSU TOPLINE DATA EXPECTED SEPT/OCT 2026; PHASE 3 SD AND COLDU ENROLLMENT ON TRACK
CELLDEX THERAPEUTICS - DISCONTINUES PHASE 2 STUDY OF BARZOLVOLIMAB IN PRURIGO NODULARIS
CELLDEX THERAPEUTICS INC: FAVORABLE SAFETY PROFILE CONSISTENT WITH PRIOR STUDIES, INCLUDING WITH NEW 450MG LOADING DOSE AND UP TO 300MGQ4W REGIMEN
CELLDEX THERAPEUTICS - PROFOUND SYSTEMIC MAST CELL DEPLETION OBSERVED IN PHASE 2 STUDY
CELLDEX THERAPEUTICS: BARZOLVOLIMAB WELL TOLERATED; LOADING DOSE FOLLOWED BY Q4W DOSING SHOW FAVORABLE SAFETY PROFILE CONSISTENT WITH PRIOR STUDIES
Source text: ID:nGNX2lQxg8
Further company coverage: CLDX.O
((((Reuters.Briefs@thomsonreuters.com;));))
Recent news on Celldex Therapeutics
See all newsUS RESEARCH ROUNDUP- Allstate, Autozone, Vertex Pharmaceuticals
U.S. STOCKS ON THE MOVE-Greenland Mines, GameStop, Shopify
Celldex shares slip as safety concerns cloud skin drug trial win (updated)
Celldex falls after two probable anaphylaxis cases in trials
Celldex's skin disease drug meets goals in two late-stage trials